Top entities: Replimune Group, United States — Food and Drug Administration, Sushil Patel, Emily G. Hilliard, Bristol Myers Squibb.

What category does this event fall under?

Regulatory — classified as securities class action.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

United States — Food and Drug Administration rejected BLA Replimune Group · Replimune Group misled investors · Schall Brown & Schwartz LLP filed class action Replimune Group

Is this event still developing?

This is an active story, last updated Aug 18, 2026. Coverage continues to evolve.

Regulatory securities class action

Replimune Securities Class Action Over FDA Rejection

Q: When did this event occur?

First reported Jul 29, 2026; last updated Aug 18, 2026.

Q: What is the market impact?

General. The FDA's rejection of Replimune's BLA and subsequent securities class actions have severely damaged investor confidence, leading to a 38% stock price drop.

Analysis based on 65 articles · First reported Jul 29, 2026 · Last updated Aug 18, 2026

Sentiment

-60

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The FDA's rejection of Replimune's BLA and subsequent securities class actions have severely damaged investor confidence, leading to a 38% stock price drop. The lawsuits could result in significant financial liabilities for Replimune and its officers, while the negative regulatory outcome may delay or prevent market approval of RP1, impacting future revenue prospects.

Biotechnology Pharmaceuticals

Event Summary

Replimune Group, a biotechnology company, faces multiple securities class action lawsuits filed by several law firms, including Pomerantz LLP, Bronstein, Gewirtz & Grossman, LLC, Levi & Korsinsky, and Schall Brown & Schwartz LLP, on behalf of investors who purchased REPL securities between October 20, 2025 and April 10, 2026. The lawsuits allege that Replimune and certain officers made false and misleading statements regarding its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with Bristol Myers Squibb's Opdivo for advanced melanoma. Specifically, the complaints claim that Replimune failed to address FDA study design concerns, submitted data from an early unplanned analysis of RP1-104 that included only 40 patients (10% of planned enrollment), and that these deficiencies were likely to cause the FDA to reject the BLA. On April 10, 2026, the FDA issued a Complete Response Letter rejecting the BLA, citing inadequate evidence of effectiveness. On July 28, 2026, the FDA published briefing documents raising concerns about the data package, causing Replimune's stock to fall 38.01% to $5.35 per share. The lead plaintiff deadline is October 5, 2026.

Key Actions

95 United States — Food and Drug Administration rejected BLA Replimune Group

95 Replimune Group misled investors

90 Schall Brown & Schwartz LLP filed class action Replimune Group

80 The Law Offices of Frank R. Cruz filed class action Replimune Group

80 Robbins LLP filed class action Replimune Group

80 Robbins Geller Rudman & Dowd LLP filed class action Replimune Group

80 Bronstein, Gewirtz & Grossman, LLC filed class action Replimune Group

80 Levi & Korsinsky filed class action Replimune Group

80 Sushil Patel named as defendant

80 Emily G. Hilliard named as defendant

70 Pomerantz LLP investigating claims Replimune Group

Entities Involved

stock

Replimune Group

Replimune is the defendant in multiple securities class actions and suffered a 38% stock price decline after the FDA rejected its BLA. The company faces potential financial damages and reputational harm.

Importance 100.0 Sentiment -80.0

govactor

United States — Food and Drug Administration

The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.

Importance 90.0 Sentiment -20.0

per

Sushil Patel

Sushil Patel, CEO of Replimune, is named as an individual defendant in the class actions. Allegations of misleading statements and failure to disclose FDA concerns could lead to personal liability.

Importance 60.0 Sentiment -70.0

per

Emily G. Hilliard

Emily G. Hilliard, CFO of Replimune, is named as an individual defendant. She is alleged to have certified misleading filings, potentially facing personal liability.

Importance 60.0 Sentiment -70.0

stock

Bristol Myers Squibb

Bristol Myers Squibb's drug Opdivo is part of the combination therapy in Replimune's BLA. The rejection may have minor negative implications for BMS, but it is not a primary defendant.

Importance 40.0 Sentiment -10.0

per

Peretz Bronstein

Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman, LLC and is named as a contact for the class action. His role is to represent investors and promote the lawsuit, but he is not directly affected by the event.